- Home
- PMM vs FDMT Comparison
PMM vs FDMT Comparison
Compare PMM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- FDMT
- Stock Information
- Founded
- PMM 1989
- FDMT 2013
- Country
- PMM United States
- FDMT United States
- Employees
- PMM N/A
- FDMT N/A
- Industry
- PMM Investment Managers
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- FDMT Health Care
- Exchange
- PMM Nasdaq
- FDMT Nasdaq
- Market Cap
- PMM 284.9M
- FDMT 268.6M
- IPO Year
- PMM N/A
- FDMT 2020
- Fundamental
- Price
- PMM $6.13
- FDMT $4.18
- Analyst Decision
- PMM
- FDMT Buy
- Analyst Count
- PMM 0
- FDMT 10
- Target Price
- PMM N/A
- FDMT $35.00
- AVG Volume (30 Days)
- PMM 118.3K
- FDMT 659.3K
- Earning Date
- PMM 01-01-0001
- FDMT 05-08-2025
- Dividend Yield
- PMM 4.68%
- FDMT N/A
- EPS Growth
- PMM N/A
- FDMT N/A
- EPS
- PMM 0.23
- FDMT N/A
- Revenue
- PMM N/A
- FDMT $37,000.00
- Revenue This Year
- PMM N/A
- FDMT $11,029.73
- Revenue Next Year
- PMM N/A
- FDMT $44.15
- P/E Ratio
- PMM $26.52
- FDMT N/A
- Revenue Growth
- PMM N/A
- FDMT N/A
- 52 Week Low
- PMM $5.00
- FDMT $3.73
- 52 Week High
- PMM $6.42
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- PMM 40.77
- FDMT 42.10
- Support Level
- PMM $6.13
- FDMT $3.73
- Resistance Level
- PMM $6.21
- FDMT $4.44
- Average True Range (ATR)
- PMM 0.06
- FDMT 0.36
- MACD
- PMM -0.02
- FDMT 0.03
- Stochastic Oscillator
- PMM 10.48
- FDMT 39.86
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.